fbpx

Tourette’s Syndrome NOE Clinical Trial

Tourette’s Syndrome NOE Clinical Trial

About this clinical trial

Current treatments for Tourette’s Syndrome (TS) are antipsychotic drugs which are often only moderately effective and result in a high incidence of side effects. Therefore, there is a need for safe and well tolerated therapies for the management of the motor, cognitive and affective symptoms of TS.  This research project is aiming to identify the optimal well tolerated dose of NOE-105 that is effective in controlling tics, without the side effects observed in currently used antipsychotic treatments.

 

Patients Required

Estimated completion

February 2022

Total participants required

5

Study location

The Wesley Hospital

Trial title

An Open-Label, Phase IIa, Multicentre, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 5mg to 15mg in adult male patients with Tourette’s Syndrome.

Eligibility

Are you between 18 and 50 years old and male by birth?

Do you have Tourette’s Syndrome and were diagnosed before you were 18 years old?

Do you have persistent motor and vocal tics that you feel are not well controlled despite being on treatment?

If your answer is yes to all the above, you may be eligible to participate in this research study.

Additional information

You can find out more about the NOE trial by visiting the ANZCTR website.

Lead investigator

Dr Philip Mosley

If you would like more information about this clinical trial, please complete the Tourette's Syndrome NOE Clinical Trial contact form

Name(Required)
Address(Required)

Wesley Medical Research

Scroll to Top